Autolus TherapeuticsAUTL
About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Employees: 647
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0.13% less ownership
Funds ownership: 63.26% [Q4 2024] → 63.13% (-0.13%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
14% less funds holding
Funds holding: 108 [Q4 2024] → 93 (-15) [Q1 2025]
34% less capital invested
Capital invested by funds: $395M [Q4 2024] → $261M (-$134M) [Q1 2025]
40% less call options, than puts
Call options by funds: $87K | Put options by funds: $145K
65% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 23
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Needham Gil Blum | 305%upside $10 | Buy Reiterated | 12 Jun 2025 |
Financial journalist opinion









